al to redefine the standard of care if approved.”

Takeda will present additional data at the conference, including pooled analyses from previously presented Phase 3 results, data evaluating the impact of oveporexton in reducing microsleeps and an evaluation of the holistic symptom impact of NT1 in the United States.

About Oveporexton (TAK-861)

Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address a broad spectrum of daytime and nighttime symptoms. The United States Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for oveporexton, with a Prescription Drug User Fee Act (PDUFA) goal
=*=*=*=*=*=
当前为第5/14页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页